DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Average Price Target from Brokerages

Key Points

• DBV Technologies S.A. has received a consensus rating of “Moderate Buy” from five analysts, with one sell, three buy, and one strong buy recommendation.
• The average 12-month price target for the stock is $14.75, with JMP Securities setting a target of $21.00 and Goldman Sachs at $7.25.
• In the latest quarterly earnings, DBV Technologies reported a loss of ($1.55) per share, significantly missing analysts' estimates of ($0.21).

Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) have earned an average rating of "Moderate Buy" from the five ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $14.75.

Several research firms recently weighed in on DBVT. JMP Securities restated a "market outperform" rating and set a $21.00 target price on shares of DBV Technologies in a report on Thursday, June 26th. Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. Lifesci Capital raised shares of DBV Technologies to a "strong-buy" rating in a research note on Thursday, June 26th. The Goldman Sachs Group raised shares of DBV Technologies to a "sell" rating and set a $7.25 price target on the stock in a research note on Thursday, May 29th. Finally, Wall Street Zen downgraded shares of DBV Technologies from a "hold" rating to a "sell" rating in a research note on Friday, July 18th.

DBV Technologies Trading Up 0.1%

Shares of DBVT traded up $0.01 during mid-day trading on Wednesday, reaching $9.88. The company had a trading volume of 5,772 shares, compared to its average volume of 187,351. The stock has a market cap of $270.58 million, a price-to-earnings ratio of -2.07 and a beta of -0.36. The firm has a fifty day simple moving average of $9.73 and a 200-day simple moving average of $8.55. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $12.78.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.34). The business had revenue of $1.74 million for the quarter, compared to analyst estimates of $0.64 million. DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. As a group, equities analysts predict that DBV Technologies will post -7.05 EPS for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nan Fung Trinity HK Ltd. bought a new stake in shares of DBV Technologies in the 2nd quarter worth about $340,000. Octagon Capital Advisors LP bought a new stake in shares of DBV Technologies in the 2nd quarter worth about $9,315,000. MPM Bioimpact LLC bought a new stake in shares of DBV Technologies in the 2nd quarter worth about $9,649,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of DBV Technologies in the 2nd quarter worth about $9,659,000. Finally, Vivo Capital LLC bought a new stake in shares of DBV Technologies in the 2nd quarter worth about $9,659,000. Hedge funds and other institutional investors own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.